Written answers

Tuesday, 25 May 2010

Department of Health and Children

Medicinal Products

2:30 pm

Photo of Maureen O'SullivanMaureen O'Sullivan (Dublin Central, Independent)
Link to this: Individually | In context

Question 173: To ask the Minister for Health and Children if she will comment on the assertion that the switching of medications from a branded drug such as fosamax or actonel, for treatment of osteoporosis, to generic alendronate is a false economy as research has shown that persons who were switched to a cheaper version of a generic drug did not show any improvement in their bone density and that patients had side effects with the cheaper generic drug. [21548/10]

Photo of Mary HarneyMary Harney (Dublin Mid West, Independent)
Link to this: Individually | In context

Over the past number of weeks I have answered a number of parliamentary questions and representations on this matter. I have made it quite clear on each occasion that with a system of generic substitution, it is important that all decisions about the interchangeability of medicines are evidence-based and take into account best practice elsewhere.

I have received the report of the joint Department of Health and Children/Health Service Executive working group established to set out a proposed model for the implementation of a system of reference pricing combined with generic substitution. The report will be published shortly. The introduction of a system of reference pricing and interchangeable medicines will promote price competition and deliver ongoing savings for both the State and for patients. I expect to see significant progress on this in 2010, including the implementation of legislative and administrative changes required to give it effect in 2011.

Comments

No comments

Log in or join to post a public comment.